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E1A-induced genes and their classification. (A) The E1A-induced genes are indicated by their accession numbers (acc. no.) and short names. 
Q–RT-PCR analysis was performed under the following conditions: (a) overexpression of E1A (not shown here; see Supplemental Table 2); (b) 
overexpression of the E1A mutant YH47/dl928 (YH47); (c) overexpression of E2F1 (E2F); and (d) removal of Rb (Rb–/–). Values were normalized 
to those obtained upon overexpression of E1A and are expressed with a color code. YH47 and E2F conditions, red/blue, > or < 35% vs. the E1A-
induced condition, respectively; Rb–/– condition, red/blue, > or < 50% vs. the E1A-induced condition, respectively. Actual values are in Supplemen-
tal Table 4, and details on each experimental condition are in Supplemental Tables 5–7. Asterisks mark nonsignificant values (P > 0.05). Early and 
late refer to activation by E1A (actual values are in Supplemental Table 3). (B) Examples of data reported in A. The bar graphs show transcript 
levels (measured by Q–RT-PCR) of representative genes, as indicated. E1A-early and -late, overexpression of E1A at early and late time points; 
mock, dl312 adenovirus control; YH47, overexpression of the E1A mutant YH47/dl928; E2F, overexpression of E2F1; MSC-E1A, overexpression 
of E1A in MSCs; Rb–/–, removal of Rb; MSC prolif., proliferating myoblasts. Values are normalized to mock-infected myotubes (assumed as 1.0). 
Results are from a single experiment; statistical analyses on repeated experiments are indicated in Supplemental Tables 2–7.
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E1A-induced genes in cell cycle and differentiation. E1A-induced genes were analyzed during cell cycle progression and MSC-differentiation. 
(A) Expression levels of representative genes, analyzed by Q–RT-PCR, during cell cycle progression of NIH-3T3. The lowest value in each 
kinetic was assumed as 1, and other values were normalized to it. Red, cell cycle regulated genes (> 10 fold); orange, poorly cell cycle regulated 
genes (4–10 fold); blue, not regulated, or marginally regulated, genes (marginally regulated, 2–4 fold: C3orf4, K0648, SF3B1; not regulated, < 2 
fold, CML66, FLJ37562, SMU-1, SKIN, and TRPC4AP). The cell cycle phase in which gene expression peaked is also indicated. (B) Examples 
of cell cycle regulation in NIH-3T3 (top), HeLa cells (middle), and MCF10A cells (bottom) of representative genes. TRPC4AP, open circles; 
SKIN, filled circles; XTP1, filled triangles; MGC22679, open triangles. (C) Representative genes were analyzed during differentiation of primary 
MSCs. MSCs were grown as proliferating myoblasts (t0) and then induced to differentiate. When committed to differentiation, myocytes undergo 
first an irreversible cell cycle arrest (characterized by block of DNA synthesis, p21 accumulation, and pRb hypophosphorylation) (t24), followed 
by phenotypic differentiation (t48) (evidenced by the accumulation of differentiation markers such as myosin heavy chain and muscle creatine 
kinase), and eventually by cell fusion (t72). Transcript levels were measured by Q–RT-PCR every 24 hours during differentiation and normalized 
to undifferentiated myoblasts (t0). Red indicates the time window in which the highest degree of regulation was detected.
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Class D genes in human tumors. (A) The overexpression of class D genes was tested by ISH on TMAs. The color code indicates the percent-
age of tumors in which overexpression was detected (actual numbers are reported in Supplemental Table 10). White, 0–20%; blue, 21–40%; 
green, 41–60%; orange, 61–80%; red, 81–100%. In almost all cases (with the exception of TRPC4AP and SF3B1 in normal colon; see Figure 4), 
normal counterparts (not reported here) showed low or undetectable levels of expression (≤ 1 on our scale; see Methods). Asterisks mark 
significant values (P < 0.05) of overexpression in tumors vs. normal counterparts. In some cases (uterus, melanoma [melan.], brain), statistical 
analysis could not be performed due to lack of normal tissues (see Supplemental Table 10 for further details). Eight other genes (from classes 
A–C, LBR, XTP1, MGC22679, K1594, C3orf4, CML66, K0648, and FLJ37562) showed no overexpression (not shown). Two additional class B 
genes (Np95 and Nasp) showed elevated mRNA levels in both tumors and proliferating cells of the normal counterparts, thus not fulfilling the 
criteria for overexpression (see text). (B) Examples of data reported in A. N, normal tissue; T, tumor. Top row, bright fields (histology); bottom 
row, dark fields (transcripts appear as bright dots). Original magnification, ×10. (C) Tumor and normal samples from colon and breast carcinoma 
patients were analyzed for levels of expression of SKIN by ISH (black bars) and Q–RT-PCR (white bars), respectively. Q–RT-PCR data are 
normalized to colon case 1N (assumed as 1.0). Data show good correlation between the 2 methods.
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Class D genes in colon cancer progression. (A) Expression of class D genes 
was evaluated by ISH in the indicated samples on TMAs. Data are expressed as 
percentage of positive samples. The absolute number of positive samples is also 
indicated at the top of each column. (B) Selected examples of the data shown in 
A. N, normal epithelium; H, hyperplastic polyp; A, adenoma; T, adenocarcinoma. 
Bright and dark fields are as in Figure 3. Original magnification, ×10. See also 
Supplemental Table 12 for statistical analysis and correlations with clinical and 
biological parameters.
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Selected class D genes predict disease outcome in breast cancer. Two class D genes (SKIN and Ch-TOG) were used together as a predictor (see 
Supplemental Methods) of prognostic outcome on 2 independent data sets, one generated in-house (A), another from van’t Veer (42) (B), and finally 
on 15 randomly selected breast tumor patients analyzed by Q–RT-PCR (C) (see Table 1 for details). Data are shown as the probability of remaining 
free of metastatic relapse, in a Kaplan-Meier plot, as a function of a favorable (dashed line) or unfavorable (continuous line) signature. See also 
Supplemental Table 13 for details. (C) Probability of remaining metastasis free is shown in a Kaplan-Meier plot, as a function of the presence of the 
favorable (dashed line) or unfavorable (continuous line) signature. In A–C, the P values indicated were calculated with the log-rank test.
Table 1
Q–RT-PCR analysis of the 2 predictive class D genes in breast 
cancer patients
Sample	 ER	 Group	 SKIN	 CH-TOG
1 pos NO 1.00 1.00
2 pos NO 0.88 1.41
3 pos NO 1.05 1.15
4 pos NO 0.42 1.12
5 pos NO 0.91 0.86
6 pos NO+ 1.75 1.10
7 pos NO+ 3.05 1.63
8 pos NO+ 2.62 1.99
9 pos NO+ 1.87 2.85
10 pos NO+ 4.02 1.62
11 pos NO+ 0.96 1.18
12 pos NO+ 0.88 0.78
13 pos NO+ 2.56 2.93
14 pos NO+ 1.60 2.33
15 pos NO+ 1.22 1.51
 50th per.  1.05 1.41
Q–RT-PCR analysis of the 2 predictive class D genes was performed 
on 15 randomly selected breast tumor patients (all lymph node negative 
at diagnosis), which were all homogeneous for ER status (ER+). The 
relevant clinical data are summarized in the group column: N0, patients 
disease free for 5 years; N0+, patients relapsed with metastatic disease 
within 5 years. The values of Q–RT-PCR are shown normalized to patient 
1 (assumed as 1.0). A 50th percentile value (50th per.) was then estab-
lished for each gene (bottom row), and a matrix was built based on the 
50th percentile value by assigning scores of 0 or 1 to values below or 
above the threshold, respectively. The sum of the 2 matrix scores was 
then used to assign favorable (score 0–1) or unfavorable (score 2) labels.
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SKIN is amplified in colon cancer, and its functional ablation reduces 


































SKIN is amplified in colon cancers. (A) Left, FISH analysis on metaphase-blocked human cell lines (MCF10A, normal epithelial cells; DLD1 and 
HT29, colon carcinoma cells). Red, SKIN probe (RP11-1139F3); green, subcentromeric 8q probe (RP11-1031I1); blue, DAPI. Insets: Details of 
the corresponding images showing FISH on chromosome 8. Original magnification, ×100. (B) FISH analysis in human colon cancer specimens 
of SKIN (red) and chromosome 8 (green). The average number of SKIN signals per cell was counted and normalized to the number of signals 
with chromosome 8 probe. Samples were considered amplified (amp.) if more than 50% of the epithelial cells presented exhibited more than 4 
signals per cell. Examples are shown: normal, normal epithelium (copies/cell = 2); tumor, not amplified (copies/cell < 4); tumor, amplified (cop-
ies/cell > 4). Insets: Details of the corresponding images showing FISH on a single cell. Original magnification, ×60. (C) The bar graph shows 
the percentage of SKIN-overexpressing samples (evaluated by ISH) in various colon specimens.
Table 2
Summary of SKIN amplification data on human cell lines 
Cell	line	 RNA	level	 Copies	 Chr.	8	 Ploidy
MCF10A 1.04 ± 0.2 4 2 2
WI38 1.22 ± 0.0 4 2 2
HMEC 2.03 ± 0.2 4 2 2
SKMEL-28 1.56 ± 0.1 10–12 5 2
DLD-1 1.89 ± 0.1 6 3 2
SW-480 2.47 ± 0.1 8 4 2
TE671 2.91 ± 0.2 8–10A 3 3–4
COLO 800 4.25 ± 0.2 6A 2 > 3
MDA-MB-361 4.31 ± 0.2 5A 3 > 3
MCF7 4.77 ± 0.4 > 10A,B 4 > 4
SKMEL-5 4.84 ± 0.1 12–14C 6 > 5
HT-29 9.26 ± 0.9 4C 2 > 6
SKBR3 9.64 ± 0.6 8A,B,C 3 > 6
Summary of amplification data on cell lines. RNA level, SKIN transcripts 
measured by Q–RT-PCR and normalized to values in MCF10A cells 
(see Supplemental Figure 4 for details); copies, number of signals 
with the SKIN RP11-1139F3 probe; chr. 8, number of signals with the 
8q RP11-1031I1 probe; ploidy, ratio between SKIN signals and chr. 8 
signals. In the column indicating copies, additional features are marked 
as follows: Atandem repeats; Bextrachromosomal copies, Chsr (homog-
enously stained region).
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Functional ablation of SKIN in tumor cell lines. Six different tumor cell lines (as indicated) were treated with SKIN-specific siRNA (open circles in 
A; RNAi in B and C) or a control scrambled oligo (filled triangles in A; scr. in B and C) or were mock treated (filled squares in A; mock in B and C). 
Twenty-four hours after treatment, cells were replated to measure cell growth (A) or analyzed for SKIN transcript levels by Q–RT-PCR (B). (A) 
Cells, replated in standard growth medium, were counted at the indicated time points. Data are expressed relative to the number of cells present 
in the plate 24 hours after replating (assumed as 1). (B) Q–RT-PCR data are expressed relative to those detected in growing MCF10A cells, 
to allow for comparison among cell lines. The mRNA levels of 2 double-stranded RNA-activated protein kinase–induced (PKR-induced) genes 
(STAT1 and interferon-induced transmembrane protein-IFITM1) were also analyzed to exclude nonspecific effects driven by SKIN-siRNA pro-
cedures and are reported on in Supplemental Figure 6. (C) In the case of DLD1 and HT-29 cells, levels of SKIN were also measured by Western 
blot with an anti-SKIN antibody. Results in A, B, and C were also replicated with a second SKIN-specific siRNA (oligo 2; see Supplemental 
Methods) with comparable results (not shown).
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